Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
Clinical trial NCT05601973 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05601973
- Sponsor
- ETOP IBCSG Partners Foundation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-27
- Primary completion
- 2024-08-24
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.